Outpatient transfusions for myelodysplastic syndromes
Patients with myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders
Myelodysplastic Syndromes (MDS)
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
Disease overview: The myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN
NCCN Grants Category 2A Recommendation to Decitabine/Cedazuridine Combo for MDS
Original Publication Date
Article Source
External Web Content
The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes (MDS) to include the combination of decitabine and cedazuridine (Inqovi) as a category 2a recommendation for the treatment of adult patients with…
New Strategies Improve Outcomes for Lower-Risk MDS
Original Publication Date
Article Source
External Web Content
Myelodysplastic syndrome (MDS) is a challenging and complicated disease with median outcomes ranging from 5.3 years in patients with lower-risk disease to just 8.4 months in the very high-risk population. 1,2 However, newly approved agents entering the armamentarium are providing…
Human and artificial intelligence to illuminate MDS
Original Publication Date
Article Source
External Web Content
In this issue of Blood, Nagata et al show for the first time that machine learning (ML) algorithms can discern patterns and identify diagnostically and prognostically relevant associations between genetic variants and cytomorphological changes in myelodysplastic syndromes (MDS)…
Silver lining: reduced relapse with chronic GVHD after transplant for MDS
Chronic graft-versus-host disease (GVHD) graft-versus-host disease (GVHD): Also called GVHD, it is a
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
For most patients with higher-risk myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez)